Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer

Tanguy Y. Seiwert*, James M. Melotek, Elizabeth A. Blair, Kerstin M. Stenson, Joseph K. Salama, Mary Ellyn Witt, Ryan J. Brisson, Apoorva Chawla, Allison Dekker, Mark W. Lingen, Masha Kocherginsky, Victoria M. Villaflor, Ezra E W Cohen, Daniel J. Haraf, Everett E. Vokes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

INIS